HDAC9 and cancer: Recent cancer research has shown that VPA, known as a histone deacetylase inhibitor (HDAC inhibitors, HDACi, HDIs) can combine with agents targeting different molecular pathways, leading to different mechanisms of action [40, 41, 42, 43].